Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 17, Issue 1, Pages 67-70Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0924-8579(00)00312-5
Keywords
ambisome; single dose; kala-azar
Ask authors/readers for more resources
Thirty four patients with parasitologically confirmed visceral leishmaniasis were divided randomly into two groups of 17. Group A received Ambisome (amphotericin B lipid complex) at a dose of 15 mg/kg body weight infused over 2 h as a single dose; patients in group B received amphotericin B deoxycholate at a dose of 1 mg/kg body infused for 2 h for 20 days. All 34 patients had a clinical, parasitological and ultimate cure. Ambisome was much better tolerated than amphotericin B, and adverse events were fewer in the Ambisome group. It was concluded that, if the cost of Ambisome were reduced, it would be a suitable first line drug. A longer study comparing three regimes of Ambisome: 15 mg/kg body weight, 11 mg/kg body weight and 7.5 mg/kg body weight, should be undertaken. (C) 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available